A Study of TYRA-300 in Children With Achondroplasia: BEACH301

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.

Conditions

Achondroplasia

Interventions / Drugs

TYRA-300 0.125 mg/kg TYRA-300 0.25 mg/kg TYRA-300 0.375 mg/kg TYRA-300 0.50 mg/kg

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment92 participants

Primary Completion—

Lead SponsorTyra Biosciences, Inc

Data Retrieved2026-04-11 04:30:22.593371+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.